Information Provided By: 
Fly News Breaks for March 19, 2019
CPRX
Mar 19, 2019 | 13:26 EDT
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $9 price target on Catalyst Pharmaceuticals, saying the initial look at the Firdapse commercial launch suggests "healthy momentum" and "strong execution" on the part of the company. The analyst also noted that Firdapse is also being investigated in two Phase 3 trials for the treatment of anti-MuSK antibody positive myasthenia gravis and congenital myasthenic syndromes, with both trials planned to read out in the second half of 2019.
News For CPRX From the Last 2 Days
There are no results for your query CPRX
